Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non‑small cell lung cancer (Review)

Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for ~85% of all lung cancer cases. Patients harboring epidermal growth factor receptor (EGFR) mutations usually develop resistance to treatment with frontline EGFR-tyrosine kinase inhi...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2021-09, Vol.22 (3), p.1, Article 646
Main Authors: Lee, Hiu Yan Jennifer, Meng, Mingjing, Liu, Yulong, Su, Tao, Kwan, Hiu Yee
Format: Article
Language:English
Subjects:
Acids
Apoptosis
Autophagy
Binding sites
Cancer therapies
Care and treatment
Cell cycle
Cellular signal transduction
Chemotherapy
Clinical trials
Drug resistance
Epidermal growth factor
Health aspects
Herbal medicine
Herbs
Kinases
Lung cancer
Lung cancer, Non-small cell
Lung cancer, Small cell
Medicinal plants
Medicine
Medicine, Botanic
Medicine, Herbal
Metastasis
Mutation
Oncology
Phosphatases
Phosphorylation
Polyphenols
Review
Tumors
Tyrosine
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for ~85% of all lung cancer cases. Patients harboring epidermal growth factor receptor (EGFR) mutations usually develop resistance to treatment with frontline EGFR-tyrosine kinase inhibitors (EGFR-TKIs). The present review summarizes the current findings and delineates the molecular mechanism of action for the therapeutic effects of herbal extracts and phytochemicals in overcoming EGFR-TKI resistance in NSCLC. Novel molecular targets underlying EGFR-TKI resistance in NSCLC are also discussed. This review provides valuable information for the development of herbal bioactive compounds as alternative treatments for EGFR-TKI-resistant NSCLC. Abbreviations: CIP2A, cancerous inhibitor of protein phosphatase 2A; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; MMP, matrix metalloproteinase; MTA-1, metastasis-associated protein-1; mTOR, mammalian target of rapamycin; NF-[kappa]B, nuclear factor-[kappa]B; NSCLC, non-small cell lung cancer; PI3K, phosphatidylinositol 3-kinase; PFS, progression-free survival; PP2A, protein phosphatase-2A; ROS, reactive oxygen species; SHP2, SH2 domain-containing phosphatase-2; STAT3, signal transduction and activator of transcription 3; TKI, tyrosine kinase inhibitor; USP8, ubiquitin-specific peptidase 8; VEGF, vascular endothelial growth factor; COX-2, cyclooxygenase-2; CDK, cyclin-dependent kinase Key words: non-small cell lung cancer, epidermal growth factor receptor, herbal medicine, Chinese medicine, drug resistance
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2021.12907